Moderna, Inc. $MRNA Shares Bought by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 235.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 46,329 shares of the company’s stock after purchasing an additional 32,504 shares during the period. Janney Montgomery Scott LLC’s holdings in Moderna were worth $1,278,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Invesco Ltd. boosted its stake in Moderna by 17.5% during the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock valued at $166,801,000 after purchasing an additional 877,162 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Moderna by 0.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,597,236 shares of the company’s stock valued at $101,982,000 after purchasing an additional 11,270 shares during the period. Northern Trust Corp boosted its stake in Moderna by 5.4% during the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company’s stock valued at $88,441,000 after purchasing an additional 160,572 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Moderna by 12.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock valued at $74,557,000 after purchasing an additional 285,662 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in Moderna by 1.8% during the 1st quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company’s stock valued at $54,382,000 after purchasing an additional 34,034 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Morgan Stanley boosted their target price on shares of Moderna from $31.00 to $32.00 and gave the company an “equal weight” rating in a research note on Friday. JPMorgan Chase & Co. set a $26.00 target price on shares of Moderna in a research note on Friday, August 1st. Evercore ISI set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. Barclays lowered their target price on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a research note on Monday, August 4th. Finally, Citigroup initiated coverage on shares of Moderna in a research note on Friday, August 1st. They set a “neutral” rating and a $40.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have assigned a Hold rating and five have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $41.81.

Moderna Price Performance

Shares of MRNA opened at $26.83 on Monday. The firm’s 50 day moving average is $25.92 and its 200-day moving average is $27.14. The stock has a market capitalization of $10.48 billion, a P/E ratio of -3.56 and a beta of 2.01. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $59.73.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analysts’ expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business’s revenue was down 41.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.